We are live on ! Find out more
KITE

Kite Pharma, Inc.
KITE

Delisted

KITE was delisted on the 2nd of October, 2017.

155 hedge funds and large institutions have $1.82B invested in Kite Pharma, Inc. in 2015 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 71 increasing their positions, 32 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

122% more repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 32

30% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 27

24% more capital invested

Capital invested by funds: $1.47B → $1.82B (+$349M)

5% more funds holding

Funds holding: 148155 (+7)

0% more funds holding in top 10

Funds holding in top 10: 66 (0)

44% less call options, than puts

Call options by funds: $19.9M | Put options by funds: $35.3M

Holders
155
Holders Change
+7
Holders Change %
+4.73%
% of All Funds
4.18%
Holding in Top 10
6
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.16%
New
35
Increased
71
Reduced
32
Closed
27
Calls
$19.9M
Puts
$35.3M
Net Calls
-$15.4M
Net Calls Change
-$13.5M
Name Holding Trade Value Shares
Change
Change in
Stake
BAMS
26
Bellevue Asset Management (Switzerland)
Switzerland
$10.7M +$399K +7,000 +4%
CPIM
27
Columbia Partners Investment Management
Virginia
$10.6M +$1.85M +32,450 +23%
CNB
28
City National Bank
California
$9.67M +$6.69M +117,273 +284%
Susquehanna International Group
29
Susquehanna International Group
Pennsylvania
$8.98M +$2.96M +51,931 +54%
GC
30
Guggenheim Capital
Illinois
$8.86M +$998K +17,495 +14%
T. Rowe Price Associates
31
T. Rowe Price Associates
Maryland
$8.37M +$7.84M +137,350 New
GL
32
GLG LLC
New York
$8.2M +$4.55M +79,685 +145%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$8.19M +$3.73M +65,370 +95%
Northern Trust
34
Northern Trust
Illinois
$7.94M +$883K +15,474 +13%
TCIM
35
TIAA CREF Investment Management
New York
$7.8M +$3.66M +64,112 +101%
RSCM
36
Rock Springs Capital Management
Maryland
$7.19M +$2.65M +46,526 +65%
Geode Capital Management
37
Geode Capital Management
Massachusetts
$6.53M +$1.36M +23,828 +29%
LCP
38
Lamond Capital Partners
California
$6.43M +$71.2K +1,248 +1%
PAMU
39
Pictet Asset Management (UK)
United Kingdom
$6.35M -$445K -7,800 -8%
BIM
40
BlackRock Investment Management
Delaware
$5.95M +$4.07M +71,290 +271%
CI
41
Capital International
California
$5.08M
CS
42
Candriam SCA
Luxembourg
$4.39M -$456K -8,000 -10%
UBS Group
43
UBS Group
Switzerland
$4.38M +$339K +5,942 +9%
CAM
44
Cormorant Asset Management
Massachusetts
$4.2M -$1.78M -31,200 -31%
RPAM
45
Rhenman & Partners Asset Management
Sweden
$4.02M +$1.2M +21,000 +47%
SIP
46
Stoneridge Investment Partners
Pennsylvania
$3.94M -$949K -16,629 -20%
New York State Common Retirement Fund
47
New York State Common Retirement Fund
New York
$3.93M -$366K -6,416 -9%
CS
48
Credit Suisse
Switzerland
$3.9M +$1.01M +17,687 +38%
Charles Schwab
49
Charles Schwab
California
$3.73M +$1.71M +29,946 +96%
BJ
50
BlackRock Japan
Japan
$3.71M +$1.53M +26,873 +79%

KITE Hedge Fund Activity: Q2 2015 in Review

155 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Kite Pharma, Inc. (KITE) for Q2 2015, worth a combined $1.82B — up 24% from $1.47B a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new KITE positions and 27 closed out — a net gain of 8 holders — while 71 added to existing stakes and 32 trimmed.

The largest buyer was Viking Global Investors, opening a new position worth an estimated $38.6M. The largest seller was Soros Fund Management, exiting entirely with an estimated $38.1M sold.

  • 155 institutional investors held Kite Pharma, Inc. (KITE) as of Q2 2015, up from 148 in Q1 2015.
  • Funds reported $1.82B of Kite Pharma, Inc. stock for Q2 2015, up 24% quarter-over-quarter.
  • 35 funds opened new Kite Pharma, Inc. positions in Q2 2015 and 27 closed out, a net change of +8 holders.
  • The largest Kite Pharma, Inc. buyer in Q2 2015 was Viking Global Investors, an estimated $38.6M added.
  • The largest Kite Pharma, Inc. seller in Q2 2015 was Soros Fund Management, an estimated $38.1M sold.

Based on aggregated 13F filings for Q2 2015.